Tag
Danish registry data (1999–2022) show large reductions in stroke across age groups with widespread oral anticoagulant (OAC) uptake, but only modest stroke gains and rising intracerebral hemorrhage in patients ≥85 years, highlighting the nee
The randomized CRRF‑PeAF trial (n=499) found cryoballoon pulmonary vein isolation non‑inferior to radiofrequency ablation for 1‑year atrial tachyarrhythmia recurrence in persistent atrial fibrillation, but radiofrequency produced greater le
Post hoc analyses of LAAOS III show surgical left atrial appendage occlusion (LAAO) during cardiac surgery lowers the proportion of cardioembolic and cortical infarcts and is associated with less disability and lower early mortality after i
The RAFF4 randomized trial found intravenous vernakalant superior to procainamide for rapid cardioversion of acute atrial fibrillation in the emergency department — higher conversion within 30 minutes, faster time to sinus rhythm, and fewer
The DECAF randomized trial found that encouraging caffeinated coffee consumption (≈1 cup/day) after successful cardioversion reduced clinically detected AF/flutter recurrence over 6 months versus caffeine abstinence (47% vs 64%; HR 0.61). R
In the ADAPT AF‑DES randomized trial, NOAC monotherapy in AF patients with drug‑eluting stents implanted ≥1 year earlier reduced bleeding and was noninferior—and numerically superior—for a composite of ischemic and bleeding outcomes versus
In patients who underwent successful catheter ablation for atrial fibrillation at least one year earlier, rivaroxaban did not significantly reduce the composite of clinical or covert embolic stroke compared with aspirin over 3 years, while
New human tissue and cellular data implicate impaired mitochondrial Ca2+ uptake, structural uncoupling of sarcoplasmic reticulum–mitochondria contacts, and oxidative stress in atrial fibrillation (AF); ezetimibe restored mitochondrial Ca2+
The AMALFI trial evaluates remote screening for asymptomatic atrial fibrillation in older adults to improve detection, anticoagulation use, and reduce stroke risk, with findings pending follow-up at 2.5 and 5 years.
The AMALFI trial demonstrates that remote, mail-based 14-day ECG patch screening modestly increases long-term atrial fibrillation detection and anticoagulation use in older adults at stroke risk, with no observed reduction in stroke at 2.5
A multicenter prospective study reveals a higher incidence but very low burden of new-onset atrial fibrillation post-CABG, challenging current anticoagulation guidelines.
This post hoc AFIRE trial analysis shows rivaroxaban monotherapy reduces major cardiovascular events and major bleeding across age groups in AF with stable CAD, with notable age-related efficacy and safety trends warranting further research
This analysis of the AZALEA-TIMI 71 trial reveals that abelacimab, a novel factor XI inhibitor, significantly reduces bleeding risk versus rivaroxaban in atrial fibrillation patients, regardless of kidney function, suggesting its promise fo
The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.
This secondary analysis of the CABANA trial reveals catheter ablation significantly benefits AF patients with fewer than three nonmodifiable recurrence risk factors, underscoring the potential for personalized treatment strategies.
A secondary analysis of the EAST-AFNET 4 trial shows early rhythm control therapy effectively reduces cardiovascular events in atrial fibrillation patients regardless of diabetes status or obesity, supporting its broad clinical use.
Serum advanced glycation end-product carboxymethyl-lysine (CML) is linked to higher risks of heart failure and atrial fibrillation in older adults, highlighting potential therapeutic targets against AGE-related cardiac dysfunction.
A large randomized study found that biomarker-based ABC-AF risk score-guided therapy did not improve stroke or death outcomes versus usual care in atrial fibrillation, highlighting the need for rigorous prospective validation of precision m
A biomarker-based ABC-AF risk score-guided treatment did not improve stroke or death outcomes versus standard care in atrial fibrillation, underscoring the need for prospective validation of precision medicine tools before clinical implemen
The RATE-AF trial demonstrates that low-dose digoxin significantly improves systolic function and symptoms in patients with heart failure, preserved ejection fraction, and permanent atrial fibrillation compared to beta-blockers, with fewer
